Performance analysis of interconnection networks for multi-cluster systems

With the current popularity of cluster computing systems, it is increasingly important to understand the capabilities and potential performance of various interconnection networks. In this paper, we propose an analytical model for studying the capabilities and potential performance of interconnection networks for multi-cluster systems. The model takes into account stochastic quantities as well as network heterogeneity in bandwidth and latency in each cluster. Also, blocking and non-blocking network architecture model is proposed and are used in performance analysis of the system. The model is validated by constructing a set of simulators to simulate different types of clusters, and by comparing the modeled results with the simulated ones.

Performance analysis of heterogeneous multi-cluster systems

When building a cost-effective high-performance parallel processing system, a performance model is a useful tool for exploring the design space and examining various parameters. However, performance analysis in such systems has proven to be a challenging task that requires the innovative performance analysis tools and methods to keep up with the rapid evolution and ever increasing complexity of such systems. To this end, we propose an analytical model for heterogeneous multi-cluster systems. The model takes into account stochastic quantities as well as network heterogeneity in bandwidth and latency in each cluster. Also, blocking and non-blocking network architecture model is proposed and are used in performance analysis of the system. The message latency is used as the primary performance metric. The model is validated by constructing a set of simulators to simulate different types of clusters, and by comparing the modeled results with the simulated ones.

Bioassay detects soluble MAdCAM-1 in body fluids

Mucosal addressin cell adhesion molecule (MAdCAM-1) is a key player in mediating the infiltration of leucocytes into chronically inflamed tissues. Five anti-MAdCAM-1 monoclonal antibodies (mAb), designated 17F5, 201F7, 314G8, 377D10 and 355G8, were generated by fusion of P3 × 63Ag8.653 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human MAdCAM-1-Fc. The latter four mAb recognize the ligand-binding first Ig domain, and block T -cell adhesion to MAdCAM-1. The non-blocking mAb 17F5 recognizes the mucin domain. Extensive analysis of a large panel of paraffin-embedded human tissues revealed that the 314G8 mAb detected MAdCAM-1 on venules in the spleen and small intestine. MAdCAM-1 was strongly expressed in the synovium of osteoarthritis patients, predominantly on the endothelial lining of blood vessels, but also within the vessel lumen. An ELISA, based on mAb 377D10 and 355G8, was developed to determine whether soluble MAdCAM-1 was present in body fluids, and to measure the levels present. The assay detected soluble MAdCAM-1 in the serum and urine of healthy donors, at levels similar to those of soluble forms of the related CAM, ICAM-1 and VCAM-1. The anti-MAdCAM-1 antibodies and assay developed here may be useful therapeutically in the treatment of inflammation in humans. Similarly, they may be useful diagnostically to monitor the presence and levels of MAdCAM-1.

Using steric bulk for selective recognition; blocking the binding site to differentiate guests

Selectivity is demonstrated in a supramolecular host:guest system using a receptor with a non-linear binding site. For the "open" receptor 1 strong binding for both flexible and rigid guests was observed. Receptor 2, with a "blocked" binding site, also bound flexible guests effectively but its affinity for rigid guests was 50 fold lower.